Exact Sciences announced that the company expects to report revenue between $550.7M-$552.7M for the fourth quarter, an increase of 16%, or 28% excluding COVID-19 testing. Consensus at $506.48M. For 2022, the company expects total revenue between $2.082B-$2.084B, an increase of 18%, or 25% excluding COVID-19 testing. Consensus at $2.03B.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EXAS:
- Exact Sciences Announces Preliminary Fourth Quarter 2022 Results
- EXACT Sciences put volume heavy and directionally bearish
- Cathie Wood’s Crystal Ball Calls for Big Jump on EXAS
- ‘Innovation Stocks Will Eventually Win’: Here Are Cathie Wood’s Top Holdings and Where They Are Headed
- Sell these stocks now, proven algorithm says
